American Bio Medica Teams With Ireland's Only Accredited Drug Testing Laboratory.

ANCRAMDALE, N.Y.--(BW HealthWire)--Feb. 25, 1998--

-- Reaches Distribution Agreement with Claymon Laboratories --

American Bio Medica Corporation (NASDAQ:ABMC) today announced that it has granted Claymon Laboratories exclusive rights to market the Rapid Drug Screen(TM) in Ireland.

Claymon Laboratories is Ireland's largest independent reference laboratory and only accredited drug testing laboratory. In addition to drugs of abuse screening, Claymon is a full service reference laboratory conducting immunologic, chemistry, blood, industrial, and other medical diagnostic tests. The laboratory's client base includes businesses, pharmaceutical firms, hospitals, and medical practitioners. Claymon is the provider for drugs of abuse testing to Ireland's prison system and also offers a chain of custody service for illicit drug screens.

"A dramatic increase in the extent of Ireland's substance abuse problem is driving industry growth in the drugs of abuse testing field," explained Clayton Bennett, Ph.D., chairman of Claymon Laboratories. "We firmly believe that on-site testing will be the procedure of choice in the future and feel the Rapid Drug Screen complements our well-established laboratory drug testing service."

According to Eamon Madden, Claymon Laboratories managing director, "We will market the Rapid Drug Screen to our existing clients, many of whom have expressed an interest in point-of-care illicit drug tests. We also see an opportunity to distribute into the retail sector through established contacts with local pharmacies, and believe a sizable market exists for home use of on-site drugs of abuse tests."

John Huss, American Bio Medica's managing director of international business, said, "Claymon Laboratories is a strategic partner for ABMC with excellent contacts in the clinical and corporate markets, transportation industry, and correctional departments throughout Ireland. It is in a unique position to provide a comprehensive and cost-effective service from distribution through positive results confirmation."

Claymon Laboratories is a Good Laboratory Practices (GLP) compliant central laboratory located in Dublin, Ireland which services clients throughout Ireland and the United Kingdom. Founded in 1991, Claymon is EN 45001 certified and was the first clinical laboratory in Ireland to receive ILAB accreditation from the National Accreditation Board in Medical and Microbiological testing.

American Bio Medica Corporation develops, manufactures, and markets rapid, inexpensive, and easy to use diagnostic kits and support services to substance abuse testing markets worldwide. ABMC's drug detection strip is proven to correlate 100% with the results produced by the SYVA EMIT II standard laboratory test.

-0-

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence upon third-party suppliers, intellectual property rights and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.

-0-

For further information, updates, and a current report, see www.otcfn.com/abmc

CONTACT: OTC Communications

Geoffrey J. Eiten, [phone] / [phone]

or

American Bio Medica

Stan Cipkowski, [phone]